996987931
ReachMD CME

Advertise on podcast: ReachMD CME

Rating
★★★★☆
4.3
from
3 reviews
This podcast has
372 episodes
Language
English
Publisher
ReachMD
Explicit
No
Date created
2015/05/20
Latest episode
2026/10/20
Average duration
11 min.
Release period
4 days

Description

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Unlock ReachMD CME podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Social media

Check ReachMD CME social media presence


Podcast episodes

Check latest episodes from ReachMD CME podcast


The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/the-edema-question-selecting-a-potassium-binder-in-patients-with-hf-or-congestion/70427/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
The Binder Selection Playbook: Matching the Right Strategy to the Right Patient
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/the-binder-selection-playbook-matching-the-right-strategy-to-the-right-patient/70431/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
Potassium Binders to Optimize GDMT Therapy in HFrEF
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/potassium-binders-to-optimize-gdmt-therapy-in-hfref/70428/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/personalized-treatment-strategies-for-hyperkalemia-bridging-evidence-and-clinical-practice-needs/48888/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
Hyperkalemia as a Barrier to GDMT: Why “Stopping GDMT” Is Often the Wrong Reflex
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/hyperkalemia-as-a-barrier-to-gdmt-why-stopping-gdmt-is-often-the-wrong-reflex/70425/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/from-lab-alert-to-action-plan-monitoring-potassium-without-undermining-cardiorenal-protection/70430/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/differentiating-oral-potassium-binders-mechanism-onset-and-sodium-load/70426/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia
2026/10/20
CME credits: 1.00 Valid until: 20-10-2027 Claim your CME credit at https://reachmd.com/cme/nephrology/ckd-diabetes-and-albuminuria-keeping-kidney-protective-therapy-on-board-despite-hyperkalemia/70429/ This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
2026/09/23
CME credits: 1.00 Valid until: 23-09-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-mild-matters-most-closing-clinical-gaps-in-early-symptomatic-alzheimers-disease/56118/ As anti-amyloid therapies reshape the management of early symptomatic Alzheimer’s disease, timely recognition, accurate diagnosis, and appropriate patient selection are increasingly important in clinical practice. In this expert-led series, Dr. David Weisman and Dr. Dani Cabral explore practical approaches to identifying patients with mild cognitive impairment or mild dementia, confirming amyloid pathology using blood-based biomarkers, CSF testing, or amyloid PET, and determining eligibility for anti-amyloid therapy. Through a patient case and practical workflows, they examine key considerations for treatment selection and individualized risk assessment, including APOE genotype, baseline MRI findings, and pre-test probability, while reviewing clinical trial evidence for lecanemab and donanemab from Clarity AD. The faculty also address the recognition and management of amyloid-related imaging abnormalities (ARIA), infusion-related reactions, MRI surveillance, treatment interruption and reinitiation, and emergency considerations. Through the series, our experts offer practical guidance for integrating anti-amyloid therapies into clinical workflows and supporting shared decision-making, multidisciplinary coordination, and informed conversations with patients and care partners. =
The Next Frontier: Addressing Persistent Cognitive Impairment in Bipolar Disorder
2026/09/18
CME credits: 0.50 Valid until: 18-09-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-next-frontier-addressing-persistent-cognitive-impairment-in-bipolar-disorder/56740/ In this MinuteCE, Drs. Jose Rubio and Sunny Tang examine the recurrent course of bipolar disorder, predictors of relapse, and the clinical burden of residual mood symptoms and cognitive impairment. They discuss limitations of current pharmacologic therapies and review dopaminergic and cholinergic neurocircuitry, with emphasis on M1 and M4 muscarinic receptors as potential therapeutic targets for mania, psychosis, and cognitive dysfunction. The discussion also examines ongoing phase 3 BALSAM-1 and BALSAM-2 trials of xanomeline-trospium for acute mania and mania with mixed features, as well as its potential role in the bipolar disorder treatment algorithm.
Recurrence as the Rule: BD Symptoms Persist and Cycle
2026/09/18
CME credits: 0.50 Valid until: 18-09-2027 Claim your CME credit at https://reachmd.com/programs/cme/recurrence-as-the-rule-bd-symptoms-persist-and-cycle/56737/ In this MinuteCE, Drs. Jose Rubio and Sunny Tang examine the recurrent course of bipolar disorder, predictors of relapse, and the clinical burden of residual mood symptoms and cognitive impairment. They discuss limitations of current pharmacologic therapies and review dopaminergic and cholinergic neurocircuitry, with emphasis on M1 and M4 muscarinic receptors as potential therapeutic targets for mania, psychosis, and cognitive dysfunction. The discussion also examines ongoing phase 3 BALSAM-1 and BALSAM-2 trials of xanomeline-trospium for acute mania and mania with mixed features, as well as its potential role in the bipolar disorder treatment algorithm.
Navigating the Limitations of Current BD Therapies
2026/09/18
CME credits: 0.50 Valid until: 18-09-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-the-limitations-of-current-bd-therapies/56738/ In this MinuteCE, Drs. Jose Rubio and Sunny Tang examine the recurrent course of bipolar disorder, predictors of relapse, and the clinical burden of residual mood symptoms and cognitive impairment. They discuss limitations of current pharmacologic therapies and review dopaminergic and cholinergic neurocircuitry, with emphasis on M1 and M4 muscarinic receptors as potential therapeutic targets for mania, psychosis, and cognitive dysfunction. The discussion also examines ongoing phase 3 BALSAM-1 and BALSAM-2 trials of xanomeline-trospium for acute mania and mania with mixed features, as well as its potential role in the bipolar disorder treatment algorithm.
Modulating the Bipolar Circuit: Striatal Dopamine and the Muscarinic Opportunity
2026/09/18
CME credits: 0.50 Valid until: 18-09-2027 Claim your CME credit at https://reachmd.com/programs/cme/modulating-the-bipolar-circuit-striatal-dopamine-and-the-muscarinic-opportunity/56739/ In this MinuteCE, Drs. Jose Rubio and Sunny Tang examine the recurrent course of bipolar disorder, predictors of relapse, and the clinical burden of residual mood symptoms and cognitive impairment. They discuss limitations of current pharmacologic therapies and review dopaminergic and cholinergic neurocircuitry, with emphasis on M1 and M4 muscarinic receptors as potential therapeutic targets for mania, psychosis, and cognitive dysfunction. The discussion also examines ongoing phase 3 BALSAM-1 and BALSAM-2 trials of xanomeline-trospium for acute mania and mania with mixed features, as well as its potential role in the bipolar disorder treatment algorithm.
Emerging Perspectives: The Potential Role of Xanomeline Trospium Across the Bipolar Spectrum
2026/09/18
CME credits: 0.50 Valid until: 18-09-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-perspectives-the-potential-role-of-xanomeline-trospium-across-the-bipolar-spectrum/56741/ In this MinuteCE, Drs. Jose Rubio and Sunny Tang examine the recurrent course of bipolar disorder, predictors of relapse, and the clinical burden of residual mood symptoms and cognitive impairment. They discuss limitations of current pharmacologic therapies and review dopaminergic and cholinergic neurocircuitry, with emphasis on M1 and M4 muscarinic receptors as potential therapeutic targets for mania, psychosis, and cognitive dysfunction. The discussion also examines ongoing phase 3 BALSAM-1 and BALSAM-2 trials of xanomeline-trospium for acute mania and mania with mixed features, as well as its potential role in the bipolar disorder treatment algorithm.
Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN
2026/08/31
CME credits: 1.00 Valid until: 31-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanisms-matter-optimizing-proteinuria-reduction-in-igan/67095/ This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Podcast reviews

Read ReachMD CME podcast reviews


4.3 out of 5
3 reviews
★★★★★
Elissa 83 2018/08/14
Scleroderma episode
Just had a patient with scleroderma, and this episode was so helpful
check all reviews on apple podcasts

Podcast sponsorship advertising

Start advertising on ReachMD CME relevant audience podcasts


What do you want to promote?